What a Skin Biopsy Actually Decides: Breslow Depth and Melanoma Staging

A skin biopsy can establish whether a suspicious lesion is melanoma, whether it remains in situ or has invaded, and which features define the primary tumor. The central measurement for invasive cutaneous melanoma is Breslow thickness: the vertical depth of invasion in millimeters. Together with ulceration, it determines the AJCC eighth-edition T category.

The biopsy does not by itself establish the complete stage. Melanoma staging uses TNM: primary tumor, regional nodes, and distant metastasis. Clinical examination, sentinel or other lymph-node pathology when performed, imaging in selected settings, and additional pathology can change the final stage; the accurate claim is that the biopsy anchors primary-tumor staging and the next decision pathway.

Key takeaways#

• The pathology report first distinguishes melanoma in situ from invasive melanoma and records the invasive tumor's maximum Breslow thickness.
• Breslow thickness is measured in millimeters to the deepest invasive melanoma cell and reported to the nearest 0.1 mm under AJCC eighth-edition conventions.
• Thickness and true tumor ulceration define the T category; mitotic rate remains informative but no longer defines T1a or T1b.
• A transected deep margin can make the reported depth a minimum, written as “at least,” and may limit the T assessment.
• Complete stage and management also depend on regional nodes, distant disease, site, biopsy completeness, other pathology features, and patient context.

What the biopsy establishes first#

Before thickness can matter, the pathologist determines what the lesion is. The report may diagnose a benign melanocytic nevus, an atypical proliferation requiring more tissue, melanoma in situ, invasive melanoma, or another skin tumor. Difficult lesions can require deeper sections, immunohistochemical stains, review by a dermatopathologist, or clinicopathologic correlation.

Melanoma in situ is confined to the epidermis. It has no Breslow thickness because no invasive melanoma extends into the dermis. It is categorized as Tis rather than placed in a thickness band. Once invasion is identified, the report should describe the maximum depth and the other required primary-tumor features.

Histologic subtype can add context. Superficial spreading, nodular, lentigo maligna, acral lentiginous, desmoplastic, and other patterns can differ in presentation and associated features. Subtype does not replace thickness and ulceration in AJCC T categorization.

The diagnosis also depends on having representative tissue. A partial sample can confirm melanoma yet miss the deepest or most diagnostically informative area. The report should spell out when sampling limits certainty.

How Breslow thickness is measured#

The pathologist examines a perpendicular section through the invasive melanoma. The measurement begins at the top of the epidermal granular layer and extends to the deepest identifiable invasive melanoma cell. If true tumor-related ulceration is present, measurement begins at the base of the ulcer. The result is reported in millimeters.[1][2]

AJCC eighth edition records thickness to the nearest 0.1 mm. A lesion may be measured more finely under the microscope, especially near a threshold, but the staging value follows the stated rounding convention. Excess decimal precision can imply reproducibility that routine tissue sections cannot support.[1]

The deepest cell can be difficult to identify when melanoma surrounds a hair follicle, tissue is tangentially cut, cells are sparse, or inflammation obscures the base, and a detached group of cells should not automatically define maximum depth without evidence that it represents contiguous invasive tumor. The pathology report can explain that uncertainty to you and may state that thickness cannot be determined.

Measurement is not the same as visible lesion height. It is a microscopic vertical measure of invasive cells in processed tissue. Millimeters and centimeters must not be confused; 0.8 mm is 0.08 cm.

The AJCC eighth-edition T categories#

The current AJCC eighth-edition cutaneous-melanoma framework uses these principal thickness bands:[1][2]

The threshold language matters. A melanoma recorded as 1.0 mm remains T1, while one recorded above 1.0 mm enters T2. For T1, the 0.8 mm boundary and ulceration create the a and b groups. At greater thicknesses, absence or presence of ulceration supplies the letter.

T category is not the same as stage group. A T1 tumor can have a different overall stage if regional nodal disease is found. Clinical stage and pathological stage can also differ because pathological staging may incorporate sentinel-node findings. A report that says pT2a does not, by that line alone, say “stage II.” Validation studies support meaningful prognostic separation across AJCC eighth-edition groups, but a group estimate is not an individual prediction,[3] and prognosis also varies with nodes, metastases, biology, treatment, age, health, and follow-up.

What ulceration means on pathology#

Ulceration is not merely a surface that looked crusted or bled. It is a microscopic finding involving loss of the full-thickness epidermis over melanoma, with associated tissue reaction used to distinguish biological ulceration from handling or biopsy artifact, and the pathologist evaluates the slide, not only the clinical description.

Trauma can remove epidermis. If the specimen is torn, superficially sampled, or previously manipulated, determining whether the loss represents true ulceration can be difficult. Current pathology protocols permit “cannot be determined” with an explanation when appropriate.[4]

Ulceration worsens the T subcategory because it is associated with prognosis. It can also affect discussion of sentinel-node staging for thin melanoma. The report should state present, not identified, or indeterminate rather than leave the field ambiguous. Extent of ulceration may also be recorded, even though it is presence or absence that drives the AJCC T letter, and that additional measure can support fuller pathologic characterization.

Mitotic rate still belongs in the report#

Mitotic rate counts tumor-cell divisions per square millimeter. It can reflect proliferative activity and remains associated with outcome. CAP's current invasive-melanoma biopsy protocol includes mitotic rate as a reportable element.[4]

AJCC seventh edition used a mitotic threshold in T1 subcategorization, and eighth edition removed mitotic rate from the T1a and T1b definition and replaced the older 1.0 mm split with the 0.8 mm threshold plus ulceration.[1][2]

“Not part of the T1 definition” does not mean “irrelevant.” Mitotic rate can contribute to clinical discussion, especially when a thin tumor has other concerning features. It simply should not be used to relabel a tumor as AJCC T1b by itself.

Clark level has a similar potential for confusion. It describes which anatomic skin layer is reached. It can appear in a pathology report, but it no longer determines the current AJCC T category. Breslow thickness is a continuous metric with better reproducibility and prognostic performance.

Why biopsy technique affects certainty#

When melanoma is suspected and anatomy permits, a complete full-thickness biopsy with a narrow clinical margin is generally preferred because it provides the whole lesion for diagnosis and depth assessment. The technique can be elliptical excision, punch excision, or a deep saucerization that captures the lesion's base. “Shave biopsy” covers both superficial and deep techniques, so the name alone does not establish adequacy.

Partial incisional or punch sampling can be appropriate for a very large lesion, a difficult anatomic site, or a lesion where complete removal would create substantial morbidity, and the sample should target the most clinically concerning area and be deep enough for the question. The requisition should identify site, lesion size, clinical concern, prior procedures, and orientation where relevant.

A superficial sample can transect invasive melanoma at the deep margin. In that setting, the pathologist may report “at least 0.7 mm,” meaning 0.7 mm was measured but melanoma continues to the specimen base. The true Breslow thickness could be greater, and a definitive T category may be impossible until more tissue is evaluated.

Transection does not mean your diagnosis is invalid or that spread occurred because of the biopsy. It means the specimen did not contain the full depth needed for a maximum measurement. Subsequent excision can find no residual tumor, residual tumor at the same depth, or a deeper focus.

Tangential sectioning creates another limitation. A slanted slice lengthens an apparent path through skin and can obscure the perpendicular vertical depth. Tissue orientation and multiple levels can help, but the report may retain a qualification when precise measurement is not defensible.

Margins answer a different question#

The biopsy report records whether melanoma reaches peripheral or deep specimen margins. A positive margin means tumor extends to a cut edge of that specimen. It does not mean the tumor has metastasized. It means local melanoma may remain at the site.

Diagnostic biopsy margins are not the same as therapeutic wide-excision margins. Initial removal often uses a narrow margin to preserve anatomy and obtain diagnosis. After invasive melanoma is confirmed, a wider excision around the scar is usually planned according to thickness, site, tissue constraints, and current guidance.

A negative biopsy margin can be reassuring about the submitted tissue but does not automatically eliminate the standard wide-excision recommendation. Histologic sampling examines sections rather than every cell along the edge, and definitive local treatment uses guideline-based clinical margins.

Deep-margin status also affects confidence in Breslow thickness. If the invasive tumor is clear of the base and the deepest point is represented, maximum depth can be measured, and if melanoma reaches the base, the depth may be only a lower bound.

Other pathology features that change the conversation#

Current synoptic reports can include microsatellites, lymphovascular invasion, neurotropism, tumor-infiltrating lymphocytes, regression, associated nevus, growth phase, and histologic subtype. These features do not all change the T category, but some affect regional staging, prognosis, or planning.

Microsatellites are separate microscopic deposits near the primary tumor that meet defined pathologic criteria. In AJCC eighth edition they contribute to the N category, even though identified in the skin specimen. They therefore demonstrate why the primary biopsy can contain information beyond T.

Lymphovascular invasion means tumor is identified within vascular spaces. Neurotropism describes tumor involving or tracking along nerves and can be particularly relevant in desmoplastic melanoma, and regression can complicate interpretation of the lesion's prior extent but does not allow a pathologist to reconstruct a greater Breslow thickness that is no longer present.

Tumor-infiltrating lymphocytes describe an immune response in the tumor. Report terminology and clinical use can vary. None of these line items should be read apart from the diagnosis, thickness, ulceration, margins, and complete staging context.

How the biopsy informs sentinel-node discussion#

Sentinel lymph node biopsy samples the first draining regional node or nodes to look for clinically occult melanoma; it is a staging procedure, not the same operation as wide local excision and not a treatment for the primary lesion.

Thickness and ulceration are major inputs. The 2024 ESMO guideline does not routinely recommend sentinel-node biopsy for pT1a melanoma, says it can be discussed in special pT1a situations such as an uncertain thickness or positive deep margin, recommends discussion for pT1b, and recommends it for clinically node-negative tumors over 1.0 mm.[5] Other current national guidelines and patient factors can shape the discussion.

The decision includes the probability that a node will be positive, the value of more accurate staging, procedural harms, whether results would affect treatment or surveillance, your health status, and your preference. A threshold in a table does not replace that conversation. If a biopsy is transected near a decision boundary, the uncertainty itself becomes part of it, and the report's “at least” wording, ulceration status, mitotic rate, and other features help the treating team decide whether additional tissue or nodal staging should be considered.

What is still needed for the complete stage#

The T category comes from primary-tumor pathology. The N category incorporates regional lymph nodes and certain local or in-transit deposits. The M category records distant metastasis, including site and other descriptors under the staging system. Clinical examination is part of every staging assessment; imaging and laboratory evaluation are selected according to stage, symptoms, and guidelines rather than used uniformly for every thin melanoma.

A definitive excision can update pathology if it finds residual invasive melanoma, microsatellites, or another relevant feature. Sentinel-node results can change pathological N status. Later evidence of distant disease changes M status. The record should distinguish the stage at diagnosis from a later recurrence.

Molecular testing answers another question. A result such as a BRAF alteration can inform treatment selection in appropriate disease settings but does not replace Breslow thickness or directly assign the AJCC T category.

The related overview of tumor-agnostic approvals explains why a molecular marker and an anatomic stage describe different dimensions of cancer.

A practical pathology-report reading order#

Begin with the exact diagnosis and whether invasion is present. Then read Breslow thickness, including any “at least” or “cannot be determined” qualifier. Check ulceration, mitotic rate, peripheral and deep margins, microsatellites, lymphovascular invasion, neurotropism, and the reported pT category.

Confirm the biopsy type and whether your whole clinical lesion was sampled. Ask whether pathology review, wider excision, sentinel-node discussion, or additional staging information is pending. Do not translate pT into a complete stage without N and M context.

Dates and specimen identity matter too. A later wide-excision report may refer back to the initial biopsy for the maximum Breslow thickness if no deeper residual tumor is present. You may need both reports to reconstruct the final primary-tumor assessment.

The site's research approach applies directly: preserve the exact measurement, its method and qualifier, and the boundary of what the specimen can establish.

References#

1. The Eighth Edition AJCC Melanoma Staging System: Implications for Treatment and Care
2. Melanoma Staging: Evidence-Based Changes in the AJCC Eighth Edition
3. External Validation of the AJCC Eighth-Edition Melanoma Staging System
4. College of American Pathologists: Invasive Melanoma Biopsy Protocol, March 2025
5. ESMO Clinical Practice Guideline for Cutaneous Melanoma